Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

摘要: Squamous cell lung cancer (SCC) represents an area of unmet need in research. For the past several years, therapeutic progress SCC has lagged behind now more common non–small histologic subtype adenocarcinoma. However, recent efforts to define complex biology underlying have begun bear fruit a multitude ways, including characterization previously unknown genomic and signaling pathways, delineation new, potentially actionable molecular targets, subsequent development large number agents directed against unique SCC-associated abnormalities. first time, SCC-specific prognostic gene signatures predictive biomarkers new are emerging. In addition, ongoing clinical trials, Lung-MAP master protocol, been designed facilitate approval targeted therapy–biomarker combinations. this comprehensive review, we describe current status therapeutics, advances understanding signatures, innovative all which offer hope for patients with advanced SCC. Clin Cancer Res; 21(10); 2236–43. ©2015 AACR . See articles CCR Focus section, “Progress Lung Cancer.”